Bortezomib Added to Daunorubicin and Cytarabine During Induction Therapy and to Intermediate-Dose Cytarabine for Consolidation in Patients With Previously Untreated Acute Myeloid Leukemia Age 60 to 75 Years: CALGB (Alliance) Study 10502
      QxMD      Google Scholar   
Citation:
J. Clin. Oncol. vol 31 (7) 923-929
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
2
Parents:
378   379   987  
Children:
None
Program:
OGC
Primary Committee:
Leukemia
Sec. Committees:
   
Pharmas:
 
Grants:
 
Corr. Author:
 
Authors:
                                 
Primary Study
CALGB-10502
Secondary Studies:
Phases:
2
Keywords:
Hema5, Hema6, Original Reports, Hematologic Malignancy